1-3 of 3
Fernando Camacho, PhD
Close
Sort by
Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-141087
Published: 2020
Journal Articles

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Donna E. Reece, MD, Faraz Zaman, MD, Young Trieu, MSc, Giovanni Piza Rodriguez, MD, Bruno Teixeira, HBSc, Kim Yoong, BSc, Phm, Fernando Camacho, PhD, Richard K Plante, MSc
Journal: Blood
Blood (2009) 114 (22): 4892.
https://doi.org/10.1182/blood.V114.22.4892.4892
Published: 2009
Journal Articles

Bortezomib [VELCADE™], Pegylated Liposomal Doxorubicin [DOXIL/CAELYX®] and Dexamethasone in the Treatment of Previously Untreated Multiple Myeloma Patients: Impact on Quality-of-Life.

Andrew Belch, MD, Donna E. Reece, MD, Nizar J. Bahlis, MD, Darrell White, MD, Bruno Teixeira, HBSc, Fernando Camacho, PHD, Richard K. Plante, MSc
Journal: Blood
Blood (2007) 110 (11): 3618.
https://doi.org/10.1182/blood.V110.11.3618.3618
Published: 2007